Cargando…
Immunotherapeutic strategies for the treatment of glioma /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London, United Kingdom :
Academic Press,
2022.
|
| Colección: | Sensitizing agents for cancer resistant to cell mediated immunotherapy ;
v. 3. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro
- Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy: Immunotherapeutic Strategies for the Treatment of Glioma
- Copyright
- Cover Image Insert
- Aims and scope of series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy��
- About the Series Editor
- Aims and Scope of Volume
- About the Volume Editors
- Preface
- Contents
- Contributors
- Chapter 1: Mechanisms of immune suppression in glioblastoma
- Introduction
- Tumor-driven mechanisms of immunosuppression in GBM
- Treatment effects: Surgery
- Treatment effects: Corticosteroid therapy
- Treatment effects: Chemotherapy and radiotherapy
- Conclusions
- References
- Chapter 2: Applied cancer immunogenomics in glioblastoma
- Introduction
- Defining neoantigens
- Discovering neoantigens: DNA/RNA sequencing
- In silico approaches to neoantigen discovery
- MHC class I predictions
- MHC class II predictions
- Discovering neoantigens: Antigen processing
- Discovering neoantigens: Mass spectrometry
- Screening neoantigen reactivity
- Neoantigens as biomarkers
- Neoantigen as targets
- Epidermal growth factor receptor variant III
- Mutant IDH1 R132H
- Personalized neoantigen vaccines
- T cell receptor (TCR) repertoire profiling
- TCR sequencing approaches
- TCR repertoires in cancer
- Conclusions and future perspectives
- Disclosures
- References
- Chapter 3: Heat shock protein vaccines in glioblastoma
- Introduction
- Immune activation in the CNS
- Vaccines for GBM
- Heat shock proteins in health and disease
- Heat shock protein-peptide complexes
- Safety and efficacy of HSPPC-96 vaccines
- HSPPC-96 vaccines in glioblastoma
- Conclusion
- References
- Chapter 4: Virotherapy treatment of central nervous system tumors
- Introduction
- Adenovirus
- Herpes simplex virus
- Measles
- Parvovirus
- Poliovirus
- Reovirus.
- Toca 511
- Vaccinia virus
- Conclusion
- Acknowledgment
- References
- Chapter 5: Adoptive cell therapy for glioma
- Introduction
- Strategies for adoptive cell therapy for glioma
- Nonspecific cell therapies
- Lymphokine-activated killer cells
- Tumor-specific cell therapies
- Tumor-infiltrating lymphocytes
- CAR T cells
- In vitro-stimulated antigen-specific T cells
- Challenges and future directions
- Conclusions
- References
- Chapter 6: Immune checkpoint blockade therapy in high-grade glioma
- Introduction
- Coinhibitory molecules: A role in homeostasis
- Preclinical and clinical studies of ICB
- Preclinical success with immune checkpoint blockade
- Clinical trials of immune checkpoint blockade in nongliomas
- Preclinical studies of immune checkpoint blockade in glioma
- Clinical trials of immune checkpoint blockade in GBM
- Why has ICB struggled in GBM?
- Tumor mutational burden/immunogenicity
- Immune infiltrate
- Additional factors
- Intracranial location
- Systemic immunosuppression
- New approaches/future directions
- Conclusion
- Acknowledgment
- References
- Chapter 7: Immunomodulatory roles of myeloid cells in gliomas
- Introduction
- Neutrophils and dendritic cells in glioblastoma biology
- Regional distribution of myeloid cells influences their prevalence and phenotype
- Circulating MDSCs
- MDSCs within the tumor microenvironment
- Intratumoral heterogeneity of macrophages/microglia
- Molecular mechanisms driving the induction, recruitment, and function of glioma-associated myeloid cells
- Interaction between bone marrow-derived macrophages and glioma
- Interaction between microglia and glioma
- Current therapeutic strategies and future directions
- References
- Chapter 8: Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated.
- Introduction
- IDO, Trp metabolism, and its association with suppressing the anticancer immune response
- Pleiotropic IDO effects reflect multiple functions, diverse cellular origins, and varying kinetics
- IDO and its relationship with host age
- Mouse models for studying IDO
- The 10,000ft view of IDOs role in adults with glioblastoma
- Concluding remarks
- Funding
- References
- Chapter 9: Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma
- Introduction
- Immunotherapy for gliomas
- Glioma and GBM microenvironment
- Chemokine receptors, chemokines, and gliomas
- Combination immunotherapy for gliomas
- CXCR4/CXCL12
- CXCR7/CXCL12
- CCR5/CCL5
- CCR2/CCL2
- CXCR2/IL-8
- Future potential of chemokine receptor antagonists for glioma treatment
- Conclusion
- References
- Index.